Cellivery Therapeutics Inc
KOSDAQ:268600
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| KR |
C
|
Cellivery Therapeutics Inc
KOSDAQ:268600
|
594.9m KRW |
Loading...
|
|
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1.1T USD |
Loading...
|
|
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
191.7B USD |
Loading...
|
|
| US |
|
Danaher Corp
NYSE:DHR
|
148.4B USD |
Loading...
|
|
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
136.2T KRW |
Loading...
|
|
| CH |
|
Lonza Group AG
SIX:LONN
|
36.3B CHF |
Loading...
|
|
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
291.5B CNY |
Loading...
|
|
| US |
|
Agilent Technologies Inc
NYSE:A
|
34.7B USD |
Loading...
|
|
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
28.2B USD |
Loading...
|
|
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
28.1B USD |
Loading...
|
|
| CN |
|
WuXi Biologics (Cayman) Inc
HKEX:2269
|
169.3B HKD |
Loading...
|
Market Distribution
| Min | -646.5% |
| 30th Percentile | 12.8% |
| Median | 19.7% |
| 70th Percentile | 32.2% |
| Max | 54 001.3% |
Other Profitability Ratios
Cellivery Therapeutics Inc
Glance View
Cellivery Therapeutics, Inc. engages in the research and development of medicine and pharmacy. The company is headquartered in Seoul, Seoul. The company went IPO on 2018-11-09. The firm develops biotherapeutics capable of entering cells in vivo through proprietary therapeuticmolecule systemic delivery technology (TSDT). The firm research and develop therapeutic drug candidates such as Parkinson’s disease treatment, pancreatic cancer and solid cancer treatment, bone formation promoter, as well as advanced obesity & type II diabetes mellitus; new drugs for research including DNA recombinase and reprogramming factors (RFs).
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Cellivery Therapeutics Inc is 2.3%, which is above its 3-year median of -10%.
Over the last 3 years, Cellivery Therapeutics Inc’s Gross Margin has increased from -28.5% to 2.3%. During this period, it reached a low of -44.7% on Sep 30, 2023 and a high of 12% on Mar 31, 2022.
